Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions

Journal of Neural Transmission

Volumn 120, Issue 8, 2013, Pages 1237-1246

  Unterecker, S ^a   Riederer, P ^a   Proft, F ^a   Maloney, J ^a   Deckert, J ^a   Pfuhlmann, B ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Antidepressant drugs; Influence of gender and age; Therapeutic drug monitoring

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; MAPROTILINE; MIRTAZAPINE; NORCLOMIPRAMINE; NORDOXEPIN; NORFLUOXETINE; NORTRIPTYLINE; SERTRALINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SERUM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 84881114640     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0952-2     Document Type: Article

References (49)

1. Alexanderson B, Evans DA, Sjoqvist F (1969) Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 4:764-768
2. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369-377
3. Balant-Gorgia EA, Balant LP (1995) Therapeutic drug monitoring. Relevance during the drug treatment of psychiatric disorders. CNS Drugs 4:432-453
4. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:1-23
5. Bengtsson F (2006) Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit 26:145-151
6. Bertilsson L, Mellström B, Sjökvist F, Martenson B, Asberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 339:560-561
7. Billups SJ, Delate T, Dugan D (2009) Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf 18:253-257
8. Brøsen K, Naranjo CA (2001) Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11:275-283
9. Carrasco-Portugal M, Flores-Murrieta FJ (2011) Gender differences in the pharmacokinetics of oral drugs. Pharmacol Pharm 2:31-41
10. Donoghue J, Taylor DM (2000) Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 13:365-383
11. Ereshefsky L (1996) Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 16:37S-50S
12. Glotzbach RK, Preskorn SH (1982) Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology 78:25-27
13. Gross AS (2001) Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 52:5S-10S
14. Gründer G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I (2011) Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 44:236-248
15. Hiemke C (1995) Therapeutisches drug monitoring von antidepressiva und neuroleptika methodische voraussetzungen. Psychopharmakotherapie 2:21-23
16. Hiemke C, Härtter S, Weigmann H (2000) Therapeutisches Drug Monitoring. In: Gastpar M, Manger M (eds) Laboruntersuchungen in der psychiatrischen Routine. Thieme, Stuttgart, pp 106-133
17. Hiemke C, Sachse J, Köller J, Weigmann H, Härtter S (2003) HPLC with column-switching for therapeutic monitoring of psychoactive drugs. Clin Lab 27:26-27
18. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195-235
19. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63:826-837
20. Hollister LE (1982) Serum concentrations of tricyclic antidepressants in clinical practice. J Clin Psychiatry 43:66-69
21. Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275-283
22. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, Greb WH (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand S350:60-75
23. Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67-76
24. Kunik ME, Pollock BG, Perel JM, Altieri L (1994) Clomipramine in the elderly: tolerance and plasma levels. J Geriatr Psychiatry Neurol 7:139-143
25. Laux G, Riederer P (1992) Plasmaspiegelbestimmung von Psychopharmaka: Therapeutisches Drug Monitoring. Wissenschaftliche Verlagsgesellschaft, Stuttgart
26. Leinonen E, Lepola U, Koponen H, Kinnunen I (1996) The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 18:111-117
27. Lundmark J, Scheel Thomsen I, Fjord-Larsen T, Manniche PM, Mengel H, Moller-Nielsen EM, Pauser H, Walinder J (1989) Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 80:76-80
28. Lundmark J, Reis M, Bengtsson F (2000) Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit 22:446-454
29. Mann K, Hiemke C, Schmidt LG, Bates DW (2006) Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 28:83-88
30. Meyer-Barner M, Meineke I, Schreeb KH, Gleiter CH (2002) Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur J Clin Pharmacol 58:253-257
31. Mitchell PB (2001) Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 52:45S-54S
32. Müller M, Dragicevic A, Fric M, Gaertner I, Grasmader K, Hartter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C (2003) Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry 36:98-104
33. Pfuhlmann B, Gerlach M, Burger R, Gonska S, Unterecker S, Jabs B, Riederer P, Deckert J (2007) Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl 72:287-296
34. Preskorn SH, Fast GA (1991) Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 52S:23-33
35. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI (2009) Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 29:39-43
36. Rao ML, Deister A, Laux G, Staberock U, Höflich G, Möller HJ (1996) Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry 29:97-102
37. Reis M, Aberg-Wistedt A, Agren H, Höglund P, Akerblad A, Bengtsson F (2004) Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 19:283-291
38. Reis M, Cherma MD, Carlsson B, Bengtsson F (2007) Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit 29:758-766
39. Reis M, Aamo T, Spigset O, Ahlner J (2009) Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 31:42-56
40. Richelson E (1997) Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 72:835-847
41. Ronfeld RA, Tremaine LM, Wilner KD (1997) Pharmacokinetics of sertraline and its N-dimethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32(S1):22-30
42. Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87-96
43. Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48:143-157
44. Tonkin AL, Bochner F (1994) Therapeutic drug monitoring and patient outcome. Clin Pharmacokinet 27:169-174
45. Ulrich S, Läuter J (2002) A comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokin 41:853-876
46. Ulrich S, Northoff G, Wurthmann C, Partscht G, Pester U, Herscu H, Meyer FP (2001) Serum levels of amitriptyline and therapeutic effect in moderate to severely, non-delusional depressed inpatients: a therapeutic window relationship. Pharmacopsychiatry 34:33-40
47. Unterecker S, Hiemke C, Greiner C, Haen E, Jabs B, Deckert J, Pfuhlmann B (2012) The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethyl-venlafaxine under naturalistic conditions. Pharmacopsychiatry 45:229-235
48. Veefkind AH, Haffmans PM, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22:202-208
49. Vuille F, Amey M, Baumann P (1991) Use of serum level monitoring of antidepressants in clinical practice. Pharmacopsychiatry 24:190-195